Company Overview and News

1
HDFC Bank, LT Infotech among top 5 momentum plays for 5-15% returns

2018-10-16 moneycontrol
The equity market opened on a cautious note but managed to close in the positive after buying in last hour of trade on October 15. It was a volatile session of trade for Nifty but it managed to close at 10,512 up by 0.38 percent.
SIFLY 523756 SRI AUROPHARMA HDB SREINFRA 524804 500180 ARBQY HDFCBANK SRIA

 
These 10 stocks were hammered in 2018, do you own any?

2018-10-09 moneycontrol
Since the turn of the year, the Indian benchmark indices have not witnessed significant erosion in value, but large cap stocks have been hit badly. Here are some of the worst performing stocks of the year, to date. The list has been compiled by Moneycontrol by sifting through the Ace Equity database. The comparative analysis undertaken here includes only the stocks of companies with market capitalisation above Rs 5,000 crore.
SUZLON SRI SREINFRA JIPKY 532617 532712 RCOM 532461 SUEL YESBANK SIFLY 523756 532627 JETAIRWAYS JPASSOCIAT 532648 SRIA YYBKY 532667 532532 PNJZY JPPOWER PNB 534809 PCJEWELLER

 
NBFC stocks feel pinch as RBI tightens noose

2018-10-09 freepressjournal.in
New Delhi: Shares of NBFCs fell up to 18.5 per cent on Monday after the Reserve Bank of India said it is looking at strengthening the guidelines to avoid situations of asset liability mismatch (ALM) by non-banking lenders. The scrip of DHFL crashed 18.52 per cent, Edelweiss Financial 13.67 per cent, Shriram City Union Finance 6.82 per cent, Cholamandalam Investment and Finance 6.07 per cent, Muthoot Capital Services 4.
523405 SIFLY 523756 SRI SREINFRA MUTHTFN MOTILALOFS SRIA 532498 511766 532892 SHRIRAMCIT JMFINANCIL

 
Sandesaras - the brothers who wanted to be oil kings

2018-10-04 livemint
Ahmedabad: In June 2016, several people, claiming to be employees of Sterling Energy and Exploration Production Ltd (SEEPCO) in Nigeria, reached out to the Indian government for help through Twitter. They had not been paid salaries for more than seven months.
SEY 508998 SIFLY 523756 STEERINTER SRI SLTHY STERLINBIO SREINFRA 512299 SRIA

 
SREI reassures stakeholders on growth amidst market turmoil

2018-09-27 moneycontrol
Srei Infrastructure Finance (Srei) reassured stakeholders about its financial health and said the current market development should not be linked to the company's growth.
SIFLY 523756 SRI SREINFRA SRIA

 
Aavas Financiers share sale subscribed 97% on last day

2018-09-27 livemint
Mumbai: The initial public offering (IPO) of Aavas Financiers Ltd was close to fully subscribed on the last day, launched in a week that saw a meltdown in stocks of non-banking finance companies.
DHFL SIFLY 523756 SRI SREINFRA 511072 CANFINHOME 511196 SRIA

 
An evening walk down Dalal Street | Indices end with cuts, Nifty below 11K at the end of September series

2018-09-27 moneycontrol
It’s a negative close for Nifty in September series and it has ended below 11,000-mark as well. The Sensex has concluded the session over 200 points lower.
YESBANK SIFLY 523756 517354 SRI HVLQY BHRYY SREINFRA 532648 YYBKY SRIA TTNQY 532540 534816 HAVELLS TCS INFRATEL

 
Srei Infrastructure Finance cracks 20% despite management#39;s assurance on liability commitments

2018-09-27 moneycontrol
Srei Infrastructure Finance's scrip fell as much as 20 percent to hit a fresh 52-week low of Rs 32 on September 27 even after the management assured stakeholders that it will be able to meet its liability commitments.
SIFLY 523756 SRI SREINFRA SRIA

 
Srei Infra Finance shares move up 5.7% on strong quarter

2018-09-06 thehindubusinessline
Shares of Srei Infrastructure Finance Ltd jumped as much as 5.7 per cent to Rs 54.6. Consolidated June-quarter profit more than doubled to Rs 140 crore, helped by higher revenue, the company said after market close on Wednesday.
SIFLY 523756 SRI SREINFRA SRIA

 
SREI Infrastructure Finance rises nearly 7% as Q1 profit jumps 114% at 139.57cr

2018-09-06 moneycontrol
Share price of SREI Infrastructure Finance added nearly 7 percent intraday Thursday as company reported strong numbers for the first quarter ended June 2018 (Q1FY19).
SIFLY 523756 SRI SREINFRA SRIA

 
Srei consolidated Q1 net up at Rs 139 crore

2018-09-05 moneycontrol
Srei Infrastructure Finance reported a consolidated net profit of Rs 139 crore, up 114 percent in the Q1 period ended June 2018, the company said.
SIFLY 523756 SRI SREINFRA SRIA

 
HUDCO, SREI Infra, Varroc results

2018-09-04 thehindubusinessline
The boards of Housing & Urban Development Corporation, SREI Infrastructure Finance and Varroc Engineering will consider quarterly results for the period ended June on Wednesday. It will be the maiden result from Varroc Engineering post listing. HUDCO had reported a profit of ₹222.52 crore on revenues of ₹1,169.66 crore in the March quarter. In the comparable year-ago period, the figures were ₹210.85 crore and ₹899.
SIFLY 523756 SRI SREINFRA SRIA

 
SREI Infrastructure up 3% as arm to sell stake in step down subsidiary; board meet on Sept 5

2018-08-24 moneycontrol
Shares of SREI Infrastructure Finance rose 3.2 percent intraday Friday as company's subsidiary is going to sell its stake in the company's step down subsidiary.
SIFLY 523756 SRI SREINFRA SRIA

 
Lenders favour Srei’s bid for Deccan Chronicle

2018-07-06 freepressjournal.in
Hyderabad : A majority in the committee of creditors for Deccan Chronicle Holdings favour Srei Infrastructure Finance’s bids to take over the company, sources said.
SRI SREINFRA IDBI 532418 532215 532662 532483 AXISBANK SIFLY 523756 500116 AXB KMBKY IBN HTMEDIA SRIA CNRYY AXBKY AXBA ICICIBANK 532174 KOTAKBANK 500247 CANBK ANDHRABANK

 
NCLT reserves order on Srei Infra’s plea against Sterling units

2018-07-02 livemint
Mumbai: The Mumbai bench of the National Company Law Tribunal (NCLT) has reserved its order in an insolvency plea filed by Srei Infrastructure Finance Ltd (SIFL) against Sterling SEZ & Infrastructure and Sterling International Enterprises, subsidiaries of Sterling Biotech, a firm that is also admitted for the resolution process. Srei has suggested the name of Vishal Jain as interim resolution professional (IRP) to the tribunal.
SIFLY 508998 523756 STEERINTER SRI SLTHY STERLINBIO SREINFRA 512299 532418 SRIA ANDHRABANK

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...